immunotherapy

Three things health execs need to know about CAR T-cell therapyHere’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
Ovarian cancer could be next application for CAR T-cell therapyWhile CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors.
Patient experience with immunotherapy: 4 things health execs need to knowCAR T-cell therapies and other immunotherapy give this oncologist’s cancer patients hope for a better quality of life.
Four oncology treatment advances to watch
Four oncology treatment advances to watchExperts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
Payers struggle to keep up with high rate of FDA drug approvalsFDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
How will immunotherapy change the future of bladder Ca care?Urology Times reached out to three urologists (selected randomly and asked them each the following question: How will immunotherapy change the future of bladder Ca care?
Connecting allergy and osmolarityThe major type 1 immunologic hypersensitivity reaction involving the conjunctiva is commonly referred to as allergic conjunctivitis.
Promising treatment developments in lymphoma immunotherapiesIn this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.
Novel immunotherapies for leukemia could raise life-threatening syndromeNovel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.
Hodgkin lymphoma: First hematologic cancer cured with immunotherapy?Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.